by Madaline Spencer | Dec 6, 2025
The U.S. Food and Drug Administration (FDA) has approved Voyxact (sibeprenlimab) for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. IgAN is a kidney disorder that occurs when IgA protein...
by Madaline Spencer | Dec 5, 2025
The U.S. Food and Drug Administration (FDA) has approved Itvisma (onasemnogene abeparvovec) for the treatment of patients ages two years and older with spinal muscular atrophy (SMA) with a confirmed mutation in the SMN1 gene. The gene therapy is administered...
by Madaline Spencer | Dec 5, 2025
Ghaith Noaiseh, MD, Associate Professor of Allergy, Clinical Immunology, and Rheumatology at The University of Kansas Medical Center, discusses the development of nipocalimab for the treatment of Sjögren’s disease (SjD). SjD is an autoimmune disorder in...
by Madaline Spencer | Dec 4, 2025
Richard Lafayette, MD, Professor of Medicine at Stanford University, discusses the ORIGIN clinical trial evaluating atacicept in adults with IgA nephropathy (IgAN). IgAN is a kidney disorder that occurs when IgA (immunoglobulin A) protein settles in the...
by Madaline Spencer | Dec 3, 2025
The U.S. Food and Drug Administration (FDA) has approved Hyrnua (sevabertinib) for the treatment of adults with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with HER2 tyrosine kinase domain activating mutations. NSCLC with HER2...
